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Abstract: Human T-cell leukemia virus type-1 (HTLV-1) is the etiological agent of adult 
T-cell leukemia (ATL), an aggressive and highly chemoresistant malignancy. Rho family 
GTPases regulate multiple signaling pathways in tumorigenesis: cytoskeletal organization, 
transcription, cell cycle progression, and cell proliferation. Geranylgeranylation of Rho 
family GTPases is essential for cell membrane localization and activation of these proteins. 
It is currently unknown whether HTLV-1-transformed cells are preferentially sensitive to 
geranylgeranylation inhibitors, such as GGTI-298. In this report, we demonstrate that 
GGTI-298 decreased cell viability and induced G2/M phase accumulation of HTLV-1-
transformed cells, independent of p53 reactivation. HTLV-1-LTR transcriptional activity 
was inhibited and Tax protein levels decreased following treatment with GGTI-298. 
Furthermore, GGTI-298 decreased activation of NF-κB,  a  downstream  target  of  Rho 
family GTPases. These studies suggest that protein geranylgeranylation contributes to 
dysregulation of cell survival pathways in HTLV-1-transformed cells. 
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1. Introduction 
An estimated 10–20 million people worldwide are infected with human T-cell leukemia virus 
type-1 (HTLV-1) [1], the etiological agent of adult T-cell leukemia (ATL) [2,3] and tropical spastic 
paraparesis/HTLV-1 associated myelopathy (TSP/HAM) [4–6]. ATL is characterized as a clonal 
lymphoproliferative disorder of CD4
+ T-lymphocytes. Approximately 3 to 5% of HTLV-1-infected 
individuals develop ATL, which presents after a long period of clinical latency that can span several 
decades [7]. Disease onset is consistent with a multi-step process of T-lymphocyte immortalization 
and transformation. The mechanism by which infected individuals develop ATL is unknown, however 
the 40 kDa viral oncoprotein, Tax, has been associated with cellular transformation [8]. 
HTLV-1 Tax is essential for viral gene expression and Tax disrupts pathways
 involved in cell cycle 
regulation, apoptosis, and DNA damage responses through direct interaction with regulatory proteins 
and regulation of nuclear factor κB  (NF-κB),  cyclic  AMP  response  element  and  activating 
transcription factor-1 (CRE/ATF-1), and serum response element (SRE) transcription pathways [8,9]. 
NF-κB transcriptional activation is triggered by phosphorylation of the upstream IκB kinase (IKK) 
complex through the phosphoinositide 3-OH kinase  (PI3K)/Akt pathway [10]. Interestingly, 
phosphorylation of the NF-κB  p65/RelA  subunit  at  serine  536  contributes  to  the  transcriptional 
inhibition of p53 in Tax-expressing cells. In HTLV-1-transformed cells, inhibition of p53 by Tax has a 
role in cell growth, cell cycle progression, and inhibition of apoptosis [11]. It has been shown 
that several chemical compounds induce apoptosis by reactivating p53 in HTLV-1-transformed 
cells [12–14].  Reactivation of p53,  or induction of apoptosis in a p53-independent manner are 
therefore ideal strategies for the development of drugs to preferentially target ATL. 
A new class of anticancer drugs has been recently demonstrated to decrease cell viability in 
multiple transformed cell lines through a p53-independent mechanism by inhibiting geranylgeranyl 
transferase 1 (GGTase-1) [15–17]. Geranylgeranyl transferase inhibitors (GGTIs), such as GGTI-298, 
inhibit a range of geranylgeranylated proteins, including the Rho family of small GTPases: Rho, Rac, 
and Cdc42 [18]. Activation of NF-κB by the Rho family has been well documented and GGTI-298 has 
been shown to affect the NF-κB pathway [17,19]. The effects of GGTI-298 are likely to be specific to 
cell type, external stimuli, and species [19,20]. In addition to regulation of NF-κB,  Rho  family 
members have been shown to regulate cellular gene transcription through CREB, SRF, and c-Jun 
transcription factor binding sites, each of which are present within Tax-responsive elements of the 
HTLV-1 promoter and have a role in viral gene expression [21–25].  Determination of whether 
HTLV-1-transformed cells are sensitive to geranylgeranyl transferase inhibitors would advance our 
understanding of how geranylgeranylated proteins regulate cell survival in these cells. 
In this report we provide evidence that treatment of HTLV-1-transformed cells with GGTI-298 
caused a significant decrease in cell viability. GGTI-298 induced G2/M phase accumulation and 
inhibited NF-κB in these cells. In contrast to other small molecule inhibitors, GGTI-298-mediated Viruses 2011, 3                      
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inhibition of NF-κB did not reactivate p53. GGTI-298 decreased Tax expression and transcriptional 
activation of the HTLV-1-LTR. Moreover, the decreased phosphorylation of IκB in GGTI-298-treated 
HTLV-1-transformed cells did not correlate with Tax protein levels. These studies suggest that protein 
geranylgeranylation contributes to dysregulation of cell survival pathways in HTLV-1-transformed cells. 
2. Results and Discussion 
2.1. GGTI-298 Decreases the Viability of HTLV-1-Transformed Cells 
We first sought to determine whether inhibitors of farnesyl transferase (FTase) or geranylgeranyl 
transferase I (GGTase I), catalysts of small GTPase prenylation, affect the viability of HTLV-1-
transformed cells. Membrane association is critical for small GTPase activation and is mediated by 
covalent addition of C15 farnesyl or C20 geranylgeranyl isoprenyl groups to cysteine residues in the 
CAAX tetrapeptide motif near or at their carboxyl terminus [26]. Ras GTPases are modified by 
farnesylation while the majority of Rho family GTPases are geranylgeranylated. To examine 
sensitivity to prenylation inhibitors, HTLV-1-transformed cell lines C8166, C91/PL, and MT2 and 
control PBMCs from three different donors were treated with DMSO solvent, 20µM FTI-277 or   
10 µM GGTI-298 (concentrations routinely used for other cancer types). As PBMCs were cultured in 
the presence of interleukin-2 (IL-2), HTLV-1-infected SP cells cultured in the presence of IL-2 served 
as an additional control to determine whether IL-2 contributed to the survival of drug-treated cells. 
Cells were harvested at 0, 24, 48, and 72 hours post-treatment. Cell viability was measured by a 
luminescent cell viability assay, which measures the ATP generated in viable cells. We found no 
significant difference in the viability of control PBMCs and HTLV-1-transformed cells treated with 
FTI-277 (Figure 1A). In contrast, the results presented in Figure 1B demonstrate that compared to 
control PBMCs, the HTLV-1-transformed cell lines were more sensitive to treatment with GGTI-298 
than were control PBMCs (Figure 1B). The viability of C8166 cells was also analyzed by trypan blue 
exclusion assays and we found decreased cell viability, similar to that seen using the luminescent assay 
(data not shown). The sensitivity to GGTI-298 varied in the HTLV-1-transformed cells with C8166 
cells being the most sensitive, followed by SP, C91/PL, and MT2 cells. 
To determine the effects of increasing GGTI-298 concentrations on cell viability, final concentrations 
of 0, 2.5, 5, and 10 µM of the drug were added to the culture media of HTLV-1-transformed, HTLV-1-
infected cells, and PBMCs for 72 hours. Following treatment, cell viability was determined. As shown 
in Figure 1C, the HTLV-1-transformed and infected cells were  more sensitive to GGTI-298 and 
showed a dose-dependent loss of viability. After 72 hours of treatment with 10 µM GGTI, control 
PBMCs showed less than 30% decrease in viability. In contrast, HTLV-1-transformed cells, C8166 
and C91/PL, and HTLV-1-infected SP cells showed a 70 to 95% reduction in viability. As above, MT2 
cells were the least sensitive of the HTLV-1-transformed cells, with a 40% decrease in viability.  Viruses 2011, 3                      
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Figure 1. GGTI-298 decreases cell viability  of Human T-cell  leukemia virus type-1 
(HTLV-1)-transformed cells. Control PBMCs from three donors and HTLV-1-transformed 
SP, C8166, C91/PL, and MT2 cells were treated with (A) 20 μM FTI-277 or (B) 10 μM 
GGTI-298. At the indicated times, cells were collected and cell viability determined. 
Values for cells treated with FTI-277 or GGTI-298 were compared to the signal for cells 
treated with DMSO solvent alone to determine percent cell viability. Error bars represent 
the standard error of the mean from three independent experiments performed in triplicate. 
(C) Control PBMCs and HTLV-1-transformed SP, C8166, C91/PL, and MT2 cells were 
treated for 72 hours with increasing amounts of GGTI-298 and cell viability measured as 
before. Error bars represent the standard error of the mean from three independent 
experiments performed in triplicate. For all GGTI298-treated cells p < 0.05 compared with 
mock-treated control, except MT2 cells treated with 2.5 and 5 μM GGTI-298. 
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2.2. GGTI-298 Induces G2/M Phase Accumulation in HTLV-1-Transformed Cells 
GGTI-298 has been shown to inhibit Rho family GTPase activation and reduce cell viability in a 
number of cancer cell types, including transformed uninfected T-cells [17,27–35]. Although PBMCs 
have a reduced proliferation compared to HTLV-1-transformed cells, GGTI-298 clearly decreased the 
viability of HTLV-1-transformed cells. Therefore, we examined its effect on cell cycle progression in 
HTLV-1-transformed C8166 and C91/PL cell lines and a Tax-negative cell line, TL-Om1. Cells were 
treated  with  DMSO  or  10  μM  GGTI-298 for 48 hours and DNA content was analyzed by flow 
cytometry after staining with propidium iodide. As shown in Figure 2, GGTI-298 caused accumulation 
of C8166 and TL-Om1 cells in the G2/M phase. GGTI-298-treated C91/PL cells showed a small 
increase in G2/M phase accumulation in C9/PL cell, indicating that the effect of GGTI-298 on cell 
cycle distribution in HTLV-1-transformed cells is cell line dependent. Though both C8166 and 
TL-Om1 cells showed a two-fold increase in the percentage of cells in G2/M phase, only TL-Om1 cells 
showed an increase in cells in G1 phase following treatment with GGTI-298. In each of the cell lines 
treated with GGTI-298, there was a decrease in the percentage of cells in S-phase of the cell cycle. 
These results demonstrate that GGTI-298 affects the cell cycle checkpoint pathways by inducing 
accumulation of HTLV-1-transformed cells in the G2/M phase of the cell cycle. This is consistent with 
other studies that show check point effects in other tumor cell lines [15,29,32,36,37]. 
Figure 2. GGTI-298 induces G2/M phase accumulation in HTLV-1-transformed cells. 
HTLV-1-transformed C8166, C91/PL, and TL-Om1 cells were treated with DMSO or 
10 μM GGTI-298. At 48 hours post-treatment, cells were fixed and stained with propidium 
iodide. Representative graphs from three independent experiments are shown for untreated 
and GGTI-298-treated C8166, C91/PL, and TL-Om1 cells. Percentage of cells in G2/M 
phase is shown above each bar. 
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2.3. GGTI-298 Inactivates the NF-κB Pathway 
GGTI-298 has been shown  to inactivate AKT and the downstream NF-κB pathway [17,19]. 
Constitutive activation of NF-κB in HTLV-1-transformed cells plays a key role in cell survival, cell 
cycle progression, and prevention of apoptosis in HTLV-1-infected cells. To determine whether 
GGTI-298 affected NF-κB activation in HTLV-1-transformed cells, C8166, C91/PL, and TL-Om1 
cells were treated with 10 µM GGTI-298 and collected at 0, 8, 24, and 48 hours post-treatment for 
immunoblot analysis. Decreased levels of IκBα, the inhibitor of NF-κB were seen by 48 hours 
post-treatment in C8166, C91/PL, and TL-Om1 cells (Figure 3A). Likewise, phosphorylated IκB 
(p-IκBα) levels decreased similarly to overall IκB levels. Interestingly, p-IκBα levels were initially 
low in TL-Om1 cells, peaked at 8 hours post-treatment, and similar to C8166 and C91/PL cells, 
decreased by 48 hours post drug treatment (Figure 3A).  
To determine whether GGTI-298 affected NF-κB transcriptional activity, real-time PCR analysis 
was performed on downstream targets of NF-κB.  Cells  were  treated  for  48  hours  with  10  μM 
GGTI-298 and total RNA was extracted and retrotranscribed. mRNA levels of the NF-κB-regulated 
genes iNOS and IL-6 were normalized to 18s RNA levels. A reduction in the levels of both NF-κB-
regulated genes was seen in all three cell lines after treatment with GGTI-298. For C8166 cells, there 
was a decrease of 65 to 80% in iNOS  and  IL-6  mRNA levels following drug treatment. While 
treatment of C91/PL and TL-Om1 cells with GGTI-298 showed a decrease of 60% and 40% in iNOS 
mRNA levels, IL-6 mRNA levels were less affected with a decrease of about 25%. These data suggest 
that the mechanism of reduction in NF-κB-regulated gene expression by GGTI-298 is likely gene and 
cell-specific. 
Figure 3. GGTI-298 inactivates the NF-κB pathway. (A) C8166, C91/PL, and TL-Om1 
cells were treated with 10 µM GGTI-298 and whole cell extracts were prepared at 0, 8, 24, 
and 48 hours post-treatment. Immunoblots using antibodies to IκB, p-IκB or actin as 
indicated.  Normalized densitometric volume is shown above each immunoblot set. 
(B) C8166, C91/PL, and TL-Om1 cells were treated with DMSO or 10 µM GGTI-298 and 
total RNA was extracted and retrotranscribed at 48 hours post-treatment. cDNA 
quantification for 18s and NF-κB targets iNOS and IL-6 was performed by real-time PCR. 
mRNA levels were normalized to 18s RNA levels from the same well. Normalized mRNA 
levels from cells treated with DMSO solvent alone was set to 1 and mRNA levels 
from drug-treated cells were determined relative to this value. Error bars represent the 
standard error of the mean from three independent experiments performed in triplicate.  
(C)  The 4×-NF-κB-Luc  luciferase reporter plasmid was cotransfected with RSV-β-
galactosidase reporter plasmid into C8166 cells. Four hours after transfection, cells were 
treated with increasing amounts of GGTI-298. Forty-eight hours after treatment with 
GGTI-298, cells were harvested and luciferase activities measured. Luciferase activity was 
normalized to β-galactosidase activity from the same well. Error bars represent the 
standard error of the mean from four independent experiments performed in duplicate. 
* p < 0.05; ** p < 0.005 compared with mock-treated control. (D) Effect of GGTI-298 on 
NF-κB DNA binding activity was assessed by EMSA using a consensus NF-κB Viruses 2011, 3                      
 
 
1821 
oligonucleotide probe. C8166 cells were treated with 10 µM GGTI-298 and nuclear 
extracts were prepared 48 hours post-treatment. For the competition assay, 200-fold molar 
excess of unlabeled consensus or mutated oligonucleotide was added to the reaction. 
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The effect of GGTI-298 on NF-κB transcriptional activity was directly analyzed using a 4×NF-κB-
Luc luciferase reporter construct. Four hours post-transfection, C8166 cells were treated with 
increasing amounts of GGTI-298 or DMSO solvent. Forty-eight hours post-treatment, cells were 
collected and luminescence was measured. Cells treated with 5 µM GGTI-298 showed 40% less 
NF-κB transcriptional activity than cells treated with DMSO alone (Figure 3C). Treatment with 10 µM 
GGTI-298 reduced NF-κB transcriptional activity by 80%.  These results suggest that GGTI-298 
inhibits NF-κB transcriptional activity in HTLV-1-infected cells. 
To further define the inhibition of NF-κB activity by GGTI-298, nuclear extracts from C8166 cells 
treated for 48 hours with 10 µM GGTI-298 were incubated with biotin-labeled NF-κB consensus 
sequence oligonucleotide probe and analyzed by electrophoretic mobility shift assay (EMSA). 
Consistent with the immunoblot and promoter activation results, GGTI-298 reduced NF-κB complex 
formation on its cognate DNA binding site (Figure 3D, lanes 1–2). The specificity of complex 
formation was demonstrated by competition assays in which excess unlabeled wild-type, but not 
mutant, NF-κB consensus oligonucleotide was able to compete for NF-κB complex formation 
(Figure 3D, lanes 3–4). Taken together, these results demonstrate that inhibition of protein 
geranylgeranylation inhibits the NF-κB pathway in HTLV-1-transformed cells. 
2.4. The Effects of GGTI-298 on HTLV-1-Transformed Cells Are p53-Independent 
Previous studies have demonstrated that Tax-mediated activation of a novel NF-κB pathway 
functionally inhibits p53 in  HTLV-1-transformed cells [10].  NF-κB and AKT inhibitors or IκB 
mutants that inhibit NF-κB activation have been reported to reactivate p53 function in Tax-expressing 
cells. As GGTI-298 inhibited NF-κB in HTLV-1-transformed cells, we asked whether GGTI-298-
induced G2/M phase accumulation and reduced viability was dependent on p53 reactivation. 
To determine whether GGTI-298 affected p53 protein levels, C8166, C91/PL, and TL-Om1 cells 
were treated with 10 µM GGTI or 9AA and whole cell extracts collected at 0, 8, 24, and 48 hours 
post-treatment for immunoblot analyses. 9AA was included as a control since it has previously been 
shown to reactivate p53 function in HTLV-1-transformed cells [14]. We found no increase in p53 
protein levels in GGTI-298-treated cells (Figure 4A). Note that the TL-Om1 cell line has a mutant 
functionally inactive p53 protein and thus we would not expect p53 to play a role in drug sensitivity in 
this cell line.  
To directly analyze the effect of GGTI-298 on p53 transcriptional activity, we transfected C8166 
cells with a p53-responsive reporter, PG13-Luc, that contains 13 repeats of the p53 response sequence 
upstream of the basal promoter driving luciferase. Four hours post-transfection, cells were treated with 
increasing amounts of GGTI-298, DMSO solvent alone or 9AA. Forty-eight hours post-treatment, 
cells were collected and luminescence measured. We observed a 4-fold increase in p53 transcriptional 
activity in cells treated with 9AA compared to cells treated with DMSO solvent alone (Figure 4B). In 
contrast, p53 transcriptional activity was not increased in cells treated with GGTI-298 at 2.5 to 10 µM 
concentrations, but rather the activity was decreased. This decrease in p53 transcriptional activity is 
consistent with the decrease in p53 protein levels (Figure 4A).  
Real-time PCR analysis was performed on downstream targets of p53 in cells treated for 48 hours 
with 10 μM GGTI-298 (Figure 4C). mRNA levels of the p53-regulated genes MDM2 and PIG3 were Viruses 2011, 3                      
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normalized to 18s RNA levels. In TL-Om1 cells, which contain a mutant p53, MDM2 and PIG3 
mRNA levels increased 65% and 15%. In contrast, MDM2 and PIG3 mRNA levels decreased 50 to 
60% in GGTI-298-treated C8166 and C91/PL cells. These results demonstrate that GGTI-298 does not 
reactivate p53 in HTLV-1-transformed cells and that the effects of GGTI-298 are p53-independent. 
Figure 4. The effects of GGTI-298 on HTLV-1-transformed cells are p53-independent. 
(A) C8166, C91/PL, and TL-Om1 cells were treated with 10 µM GGTI-298 or 9AA and 
whole cell extracts were prepared at 0, 8, 24, and 48 hours post-treatment. Immunoblots 
using antibodies to p53 or actin as indicated. Normalized densitometric volume is shown 
above each immunoblot set. (B) PG13-Luc luciferase reporter plasmid was cotransfected 
with RSV-β-galactosidase reporter plasmid into C8166 cells. Four hours after transfection, 
cells were treated with increasing amounts of GGTI-298 or 10 µM 9AA. Forty-eight hours 
after treatment with GGTI-298, cells were harvested and luciferase activities measured. 
Luciferase activity was normalized to β-galactosidase activity from the same well. Error 
bars represent the standard error of the mean from three independent experiments 
performed in duplicate. * p < 0.05; ** p < 0.005 compared with mock-treated control. 
(C) C8166, C91/PL, and TL-Om1 cells were treated with DMSO or 10 µM GGTI-298 and 
total RNA was extracted and retrotranscribed at 48 hours post-treatment. cDNA 
quantification for 18s and p53 targets MDM2 and IL-6 was performed by real-time PCR. 
mRNA levels were normalized to 18s RNA levels from the same well. Normalized mRNA 
levels from cells treated with DMSO solvent alone was set to 1 and mRNA levels from 
drug-treated cells were determined relative to this value. Error bars represent the standard 
error of the mean from three independent experiments performed in triplicate. 
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Figure 4. Cont. 
 
2.5. GGTI-298 Inhibits Transcription of the HTLV-1-LTR and Decreases Tax Expression 
In addition to regulation of NF-κB, Rho family members have been shown to regulate transcription 
of cellular genes through CREB, SRF, and c-Jun transcription factor binding sites, each of which are 
present in the Tax-responsive elements of the HTLV-1 promoter and have a role in viral gene 
expression [21–25]. Thus we next examined whether GGTI-298 affected transcriptional activation of 
the viral promoter. Real-time PCR analysis was performed on tax/rex mRNA levels in C8166 and 
C91/PL cells treated for 48 hours with 10 μM GGTI-298 (Figure 5A). As before, target mRNA levels 
were normalized to 18s RNA levels. We found a 50% decrease in tax/rex mRNA levels in both C8166 
and C91/PL cells following drug treatment.  To determine whether GGTI-298 affects Tax protein 
expression, C8166 cells were collected for immunoblot analysis at 0, 8, 24, and 48 hours after 
treatment with GGTI-298. We found that Tax protein levels decreased approximately 75% after   
24 hour treatment with GGTI-298 (Figure 5B). C8166 cells were treated with increasing amounts of 
GGTI-298 four hours after being transfected with an HTLV-1-LTR-luciferase construct. Cells were 
collected 48 hours post-treatment and luminescence was measured. We found a dose-dependent 
repression of viral promoter activity by GGTI-298 (Figure 5C). C8166 cells treated with 10 µM 
GGTI-298 showed 95% less HTLV-1 promoter activity as compared to cells treated with DMSO 
solvent alone. The decrease in HTLV-1-LTR activity in GGTI-298-treated C8166 cells may be in part 
due to diminishment of CRE pathway activity. In a CRE-luciferase reporter assay, we measured a 50% 
decrease in luciferase levels in C8166 cells treated with 10 μM GGTI-298 for 48 hours (data not 
shown). Together, this data shows that GGTI-298 significantly inhibits transcription of the HTLV-1-
LTR and decreases Tax expression. 
Thus, deactivation of NF-κB and accumulation of cells in G2/M phase in GGTI-298-treated HTLV-
1-transformed cells may be, in part, due to decreased Tax expression and activity following inhibition 
of transcription pathways by GGTI-298. Indeed, preliminary experiments from another lab revealed 
that an HTLV-1-infected human T-cell line could not survive knockdown of Tax protein levels after 
being infected with a lentivirus that encoded siRNA targeting Tax [38].  Viruses 2011, 3                      
 
 
1825 
Figure 5. GGTI-298 inhibits transcription of the HTLV-1-LTR and decreases Tax 
expression. (A) C8166 and C91/PL cells were treated with DMSO or 10 µM GGTI-298 
and total RNA was extracted and retrotranscribed at 48 hours post-treatment. cDNA 
quantification for tax/rex and 18s was performed by real-time PCR. mRNA levels were 
normalized to 18s RNA levels from the same well. Normalized mRNA levels from cells 
treated with DMSO solvent alone was set to 1 and mRNA levels from drug-treated cells 
were determined relative to this value. Error bars represent the standard error of the mean 
from three independent experiments performed in triplicate. (B) C8166 cells were treated 
with 10 µM GGTI-298 and whole cell extracts were prepared at 0, 8, 24, and 48 hours 
post-treatment. Immunoblots using antibodies to Tax or actin as indicated. Normalized 
densitometric volume is shown at top. (C) HTLV-1-LTR-Luc luciferase reporter plasmid 
was cotransfected with RSV-β-galactosidase reporter plasmid into C8166 cells. Four hours 
after transfection, cells were treated with increasing amounts of GGTI-298. Forty-eight 
hours after treatment with GGTI-298, cells were harvested and luciferase activities 
measured. Luciferase activity was normalized to β-galactosidase activity from the same 
well. Error bars represent the standard error of the mean from three independent 
experiments performed in duplicate. ** p < 0.005 compared with mock-treated control. (D) 
C8166 cells were infected with adenovirus expressing either GFP (Ad-GFP) or Tax (Ad-
Tax). At 24 hours post-infection, cells were treated with 10 µM GGTI-298. At 48 hours 
post-infection, whole cell extracts were prepared and immunoblots were performed using 
antibodies to Tax, p-IκB, or actin as indicated. Normalized densitometric volume is shown 
above each immunoblot set. (E) The 4×-NF-κB-Luc or (F) HTLV-1-LTR-Luc luciferase 
reporter plasmid was cotransfected with RSV-β-galactosidase reporter plasmid into C8166 
cells. Twenty-four hours post-transfection, cells were infected with Ad-GFP or Ad-Tax 
and treated 4 hours later with 10 µM GGTI-298. Forty-eight hours after treatment with 
GGTI-298, cells were harvested and luciferase activities measured. Luciferase activity was 
normalized to β-galactosidase activity from the same well. Error bars represent the 
standard error of the mean from three independent experiments performed in duplicate. 
* p < 0.05; ** p < 0.005 compared with mock-treated control. 
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Figure 5. Cont. 
 
 
We next determined whether the effect of GGTI-298 on the NF-κB pathway was due to decreased 
Tax protein expression in Tax positive cells [28]. C8166 cells were infected with either an adenovirus 
construct that expresses Tax (Ad-Tax) or GFP (Ad-GFP). Twenty-four hours post-infection, cells were 
treated with 10 µM GGTI-298 and incubated an additional 24 hours. Immunoblots were then 
performed and phosphorylation status of IκB analyzed (Figure 5D). As expected from previous 
experiments (Figure 3A), GGTI-298 decreased the levels of phosphorylated IκB in cells infected with 
Ad-GFP and Ad-Tax as compared to control treated cells. Interestingly, GGTI-298 reduced Tax 
protein levels in cells infected with the Ad-Tax construct (Figure 5D, lanes 3–4). Importantly, 
however, Tax protein expression was still significantly higher than in mock-treated cells infected with 
the Ad-GFP construct (Figure 5D, lane 1). Despite the high level of Tax expression, p-IκB levels still 
decreased in response to GGTI-298 treatment (Figure 5D). In addition, increased Tax expression did 
not abrogate the effects of GGTI-298 on NF-κB (Figure 5E) or HTLV-1-LTR (Figure 5F) 
transcriptional activity. In mock-treated cells expressing Ad-Tax, there was a four-fold increase in 
NF-κB transcriptional activity and a two-fold increase in HTLV-1-LTR activation compared to cells 
expressing Ad-GFP. Treatment of Ad-Tax and Ad-GFP expressing cells with GGTI-298 significantly Viruses 2011, 3                      
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inhibited NF-κB transcriptional activity and HTLV-1-LTR activation. While Ad-Tax activity was able 
to augment basal Tax-mediated transcriptional transactivation, it was unable to counter the effects of 
GGTI-298 on transcriptional repression. Together these results indicate that GGTI-298 decreases Tax 
protein levels and HTLV-1-LTR activity and that deactivation of the NF-κB pathway by the inhibitor 
does not correlate with Tax expression. 
2.6. Discussion 
Rho family GTPases regulate multiple signaling pathways that control cytoskeletal organization, 
transcription, cell cycle progression and cell proliferation. Overexpression of multiple Rho family 
members in human tumors suggests that these proteins are important in tumorigenesis and therefore 
potential candidates for therapeutic intervention [39]. Currently, a role for Rho family GTPases in the 
development of ATL is emerging. First, Tax has been reported to form complexes with several 
members of the Rho family including RhoA, Rac, Gap1m and Cdc42 [40]. Second, microarray 
analysis showed altered gene expression of numerous Rho GTPase and GTPase-binding proteins in 
ovine B-cells expressing bovine leukemia virus Tax (TaxBLV) [41]. Third, bisphosphonate incardonate, 
a compound that disrupts protein farnesylation and geranylgeranylation, has recently been 
demonstrated to induce apoptosis in HTLV-1-transformed cells [42]. Fourth, Nonaka et al. reported 
that inhibition of geranylgeranylation, but not farnesylation, induced apoptosis in HTLV-1-infected 
ATL cell lines [28]. Nonaka et al. further reported that the Rho family GTPases Rab5B and Rac1A 
were found to be prenylated in these cells. However, the authors did not define the mechanism used by 
GGTI-298 to cause cell death in the HTLV-1-transformed cells. 
Here, we show that the prenylation inhibitor GGTI-298 decreased cell viability and induced G2/M 
phase accumulation in HTLV-1-transformed cells in a p53-independent manner. In contrast, the 
prenylation inhibitor FTI-277 did not affect cell viability in these cells. Treatment of HTLV-1-
transformed cells with GGTI-298 decreased activation of the NF-κB signaling pathway. In addition, 
HTLV-1-LTR transcriptional activity was inhibited and Tax protein levels decreased following 
treatment with GGTI-298. The results of these experiments suggest a decrease in cellular transcription 
whose pattern differs by gene and cell type. However, more pathways need to be examined to 
determine specificity. We hypothesize that activated Rho family GTPases have a role in several cell 
signaling pathways that are dysregulated in HTLV-1-transformed cells and that geranylgeranyl 
transferase inhibitors may provide a novel class of therapeutic agents for treatment of ATL. 
GGTI-298 may be useful for the study of other functions of Rho GTPases in HTLV-1-infected 
cells such as cell adhesion, migration, and chemotaxis. ATL is characterized by infiltration of 
circulating ATL cells into a variety of tissues. Fresh ATL cells from patients express lymphocyte 
function-associated antigen 1 (LFA-1) [43]. LFA-1 mediates adhesion of circulating leukocytes to 
endothelial ligands and mediates transendothelial migration of ATL cells [44]. Recently, it has been 
shown that GGTI-298 is able to diminish LFA-1 expression in T-acute lymphoblastic leukemia cells 
by inhibiting the GTPase Rap1b [45]. Interestingly, HTLV-1 p8 increases clustering of LFA-1 on the 
cell surface to enhance cell-cell adhesion to promote viral spread [46,47]. By demonstrating here that 
HTLV-1-transformed cells are sensitive to GGTI-298, we speculate that this compound could disrupt 
HTLV-1 p8-mediated modulation of cell adhesion in  these cells by inhibiting LFA-1 clustering. Viruses 2011, 3                      
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Continued study and characterization of geranylgeranylated proteins, such as Rho family GTPases, 
will increase our understanding of the mechanisms that regulate infection and transformation of 
HTLV-1-infected cells. 
3. Experimental Section  
3.1. Preparation of PBMCs 
Heparinized human peripheral blood was obtained from healthy volunteers at the NIH 
clinical center. Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors using 
Ficoll-Paque Plus  (GE Healthcare, Chalfont St. Giles, UK) according to the manufacturer’s 
instructions. Isolated lymphocytes were washed in PBS and activated in the presence of 2 μg/mL 
phytohemagglutinin-L (PHA-L) for 24 hours before being cultured in RPMI media supplemented with 
20% FBS, 2 mM L-glutamine, penicillin/streptomycin and 50 U/mL interleukin-2 (IL-2). 
3.2. Cell Lines and Drug Treatment  
The HTLV-1-transformed cell lines  C8166, C91/PL, and MT2, the ATL cell line TL-Om1 
were maintained in RPMI media supplemented with 10% FBS, 2 mM L-glutamine and 
penicillin/streptomycin. IL-2-dependent HTLV-1-infected SP cells were cultured in RPMI media 
supplemented with 20% FBS, 2 mM L-glutamine, penicillin/streptomycin and 50 U/mL IL-2. FTI-277 
(Sigma, St. Louis, MO, USA), GGTI-298 (Sigma, St. Louis, MO, USA) and 9-aminoacridine (9AA) 
(Sigma, St. Louis, MO, USA) were solubilized in dimethyl sulfoxide (DMSO) (Sigma, St. Louis, MO, 
USA). During drug treatment, mock treated cells were cultured in an equal amount of DMSO (0.1%). 
3.3. Whole Cell and Nuclear Extracts Preparation  
Approximately 5 × 10
6 cells were washed in 0.5 volumes of cold 0.01 M PBS and pelleted. For 
whole cell extract preparation, cells were incubated in cell lysis buffer (50 mM Tris-HCl, pH 7.4, 
120 mM NaCl, 5 mM EDTA, 0.5% NP-40, 0.2 mM Na3VO4, 50 mM NaF) with 1 mM DTT, 1 mM 
PMSF, and protease inhibitors on ice for 20 minutes, centrifuged and the supernatant collected. For 
nuclear extract preparation, cells were lysed with NE-PER Nuclear and Cytoplasmic Extraction Reagents 
according to manufacturer’s instructions (Pierce, Rockford, IL, USA). Protein concentrations were 
determined by Bradford assay. 
3.4. Immunoblot Analysis 
Protein samples of 20 to 50 μg  was  separated  by  sodium  dodecyl  sulfate-polyacrylamide gel 
electrophoresis (4–12% or 12%) in MES SDS running buffer (Invitrogen, Carlsbad, CA, USA) and 
transferred to Immobilon-P membranes (Millipore, Billerica, MA, USA). The membranes were 
blocked with PBS containing 0.1% Tween and 2.5% nonfat dried milk, dried and then probed with the 
appropriate primary and horseradish peroxidase-conjugated secondary antibodies. Immunoreactivity 
was detected with SuperSignal West Pico chemiluminescent substrate
 (Pierce, Rockford, IL, USA). 
Densitometric volume analyses were performed with AlphaEase FC (Alpha Innotech, Santa Clara, CA, Viruses 2011, 3                      
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USA) [48]. Protein levels were normalized to actin levels from the same well. Normalized protein 
levels were compared with control protein level, which was set to 1, to determine relative 
protein levels. 
3.5. Antibodies 
IκB, p-IκB, (Cell Signaling, Danvers, MA, USA), actin (Sigma, St. Louis, MO, USA), and p53 
(Calbiochem, San Diego, CA, USA), primary antibodies and horseradish peroxidase-conjugated 
secondary antibodies (GE Healthcare, Chalfont St. Giles, UK) were purchased. Tab172 monoclonal 
antibodies were used to detect the expression of Tax protein. 
3.6. Cell Viability Assays  
Cell viability assays were performed using the CellTiter-Glo  luminescent cell viability 
assay (Promega, Madison, WI, USA) according to the manufacturer’s instructions. Briefly, 
2.5 × 10
5 cells/mL were cultured in sterile 96-well plates in the presence of GGTI-298 or DMSO in 
RPMI medium. Following incubation, 100 μL of CellTiter-Glo reagent was added to lyse the cells. 
The contents were mixed on a rocker for 2 minutes and then incubated at room temperature for 
10 minutes. Luminescence was recorded in a luminometer with an integration time of 1 second per 
well. The luminescent signals from the GGTI-298-treated cells were normalized to the luminescent 
signal from cells treated with DMSO alone, which was arbitrarily set to 100%. 
3.7. Flow Cytometry Analysis of Cell Cycle Progression 
One to 2 × 10
6 cells were treated with 10 μM GGTI-298 or DMSO for 48 hours, washed in PBS, 
and fixed in 5 mL 70% ethanol overnight at −20 °C. Cells were washed in PBS and stained with 
0.5 mL  propidium  iodide  staining  buffer  (50  μg/mL  propidium  iodide  diluted  in  PBS  with  0.1% 
Triton-X-100) for 20 minutes. Samples were acquired on a FACSCalibur flow cytometer using ModFit 
LT software (Verity Software House, Topsham, ME, USA) [49] and data was analyzed using FlowJo 
software (Tree Star, Ashland, OR, USA) [50]. 
3.8. Transfection and Luciferase Assays 
Three to 4 × 10
6 cells were transfected with 1 µg RSV-β-galactosidase and 4 µg 4×-NF-κB-Luc, 
PG13-Luc, or HTLV-1-LTR-Luc luciferase reporter plasmids by nucleofection with Human T-cell 
Nucleofector Kit/nucleofection program U-014 (Amaxa, Gaithersburg, MD,  USA) according to 
manufacturer’s instructions. All plasmids were previously described [13]. Immediately after 
nucleofection, 5 × 10
5 cells/well were distributed on 24 well-plates. Four hours after nucleofection, 
cells were treated with GGTI-298, 9AA or DMSO. Forty-eight hours after treatment, cells were lysed 
in passive lysis buffer and luciferase activity was measured using the dual luciferase reporter assay 
system (Promega, Madison, WI, USA) and Galactolight assay kit (Tropix, Bedford, MA, USA). 
Luminescence was recorded in a luminometer with an integration time of 12 seconds per sample. 
Luciferase activity was normalized to β-galactosidase activity from the same well. Normalized Viruses 2011, 3                      
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luciferase activity from cells treated with DMSO solvent alone was set to 1 and luciferase values from 
each drug concentration were determined relative to this value. 
3.9. Real-Time PCR 
For real-time PCR analysis, 1 × 10
6  cells  were  treated  with  10  μM  GGTI-298 or DMSO for 
48 hours. Cells were washed in PBS and total RNA was extracted from all samples with RNeasy Plus 
(Qiagen, Valencia, CA, USA) and retrotranscribed with Quantitect Reverse Transcription kit (Qiagen, 
Valencia, CA, USA), according to manufacturer’s instructions. The cDNA quantification for 18s, IL6, 
iNOS, MDM, PIG3 and tax/rex was performed by real-time PCR using an ABI 7000. Reactions were 
performed using a SYBR FAST PCR mix (Kapa Biosystems, Woburn, MA, USA), following the 
manufacturer’s instructions. Primer sequences were designed to specifically amplify:  
18s, 5'-GCCCGAAGCGTTTACTTTGA-3' (forward) and  
5'-TCCATTATTCCTAGCTGCGGTATC-3' (reverse);  
IL6, 5'-GGTACATCCTCGACGGCATC-3' (forward) and  
5'-CCAGTGCCTCTTTGCTGCTT-3' (reverse);  
iNOS, 5'-CAAGGCATCCTGGAGCGAGT-3' (forward) and  
5'-GTAGGTGAGGGCCTGGCTGA-3' (reverse);  
MDM, 5'-GGTTGACTCAGCTTTTCCTCTTG-3' (forward) and  
5'-GGAAAATGCATGGTTTAAATAGCC-3' (reverse); PIG3,  5'-CACTCCCAACGGCTCCTTT-3' 
(forward) and 5'-GCCCATCTTGAGCATGGGTG-3' (reverse); tax/rex  primers were previously 
described [51]. Results were expressed as ΔΔCt, where Ct is the cycle threshold, and presented as 
ratios between the target gene and the 18s housekeeping RNA. Normalized mRNA levels from cells 
treated with DMSO solvent alone was set to 1 and mRNA levels from drug-treated cells were 
determined relative to this value. 
3.10. Electrophoretic Mobility Shift Assays (EMSAs) 
The sequence used for NF-κB consensus wild-type oligonucleotide was 
5'-AGTTGAGGGGACTTTCCCAGGC-3', while the NF-κB mutant oligonucleotide was 
5'-AGTTGAGGCGACTTTCCCAGGC-3'. Double-stranded NF-κB consensus wild-type oligonucleotide 
was labeled with biotin-11-dUTP (Pierce, Rockford, IL, USA). EMSA reactions included 10× EMSA 
buffer (100 mM Tris pH7.5, 500 mM KCl, 10 mM DTT, 2.5% glycerol, 5 mM MgCl, 50 ng 
poly(dI/dC), 2.5 µg nuclear extract and approximately 20 fmol labeled probe in a 20 µL total reaction 
volume. For competition assays, approximately 200-fold molar excess of unlabeled oligonucleotide 
was added to the reaction. Reactions were incubate6+d at room temperature for   
20 minutes. Complexes  were resolved on a 5% nondenaturing polyacrylamide gel in 0.5× TBE. 
Following electrophoresis, binding reactions were transferred to a Biodyne B membrane (Pierce, 
Rockford, IL, USA) and complexes were detected by streptavidin-horseradish peroxidase 
chemiluminescent substrate. Viruses 2011, 3                      
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3.11. Adenovirus Infection of Cells 
An adenovirus-Tax (Ad-Tax) construct provided by M. Yoshida and an adenovirus-green 
fluorescent protein (Ad-GFP) construct (Q-Biogene, Montréal, Canada) were used to infect   
HTLV-1-transformed C8166 cells (1 × 10
6  cells) in RPMI media not supplemented with serum. 
The adenovirus constructs were previously described [52]. At three hours post-infection, cells were 
washed and resuspended in RPMI media supplemented with 10% FBS, 2 mM L-glutamine and 
penicillin/streptomycin. The infected cells were incubated for 24 hours for GFP and Tax expression 
and then treated with 10 µM GGTI-298 for an additional 24 hours.  
3.12. Statistical Analysis 
Data were analyzed by Student’s two-sample equal variance t  test with a p  value of <0.05 
considered significant. 
4. Conclusions 
In conclusion, we have demonstrated that treatment of HTLV-1-transformed cells with GGTI-298, 
a prenylation inhibitor that inhibits geranylgeranylation, decreased cell viability and induced G2/M 
phase accumulation. The effects of GGTI-298 observed in HTLV-1-transformed cells suggest an 
important role for geranylgeranylated proteins in cell survival and cell cycle progression. Continued 
study and characterization of geranylgeranylated proteins, such as Rho family GTPases, will increase 
our understanding of the mechanisms that regulate transformation of HTLV-1-infected cells. 
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